Liver Enzyme Elevations in Dogs: Diagnostic Approach*

Total Page:16

File Type:pdf, Size:1020Kb

Liver Enzyme Elevations in Dogs: Diagnostic Approach* 3 CE CREDITS CE Article 2 Liver Enzyme Elevations in Dogs: Diagnostic Approach* ❯❯ Lucia Alvarez, DVM Abstract: Increased liver enzyme activities are sensitive indicators of hepatic disease, but their ❯❯ Jacqueline C. Whittemore, limited specificity can make their interpretation a challenge. A stepwise approach to diagnosing the a DVM, PhD, DACVIM source of increased liver enzyme activity involves characterization of the clinical picture, identifica- University of Tennessee tion of the predominant enzyme activity pattern, elimination of common extrahepatic diseases, and a systematic diagnostic workup for hepatobiliary disease. Comprehensive hepatobiliary testing includes a complete blood count, biochemical profile, and urinalysis; coagulation and liver function tests; abdominal imaging; bile cytology and culture; and liver biopsy for histopathology, culture, and metal analysis. At a Glance lterations in circulating liver en - atocellular injury and cholestasis and may zyme activities may present a be caused by concurrent disease pro- Signalment, History, and Adiagnostic challenge because they cesses or progressive disorders. Physical Examination are common, often nonspecific biochemi- The magnitude and duration of increase Page 416 cal findings. A systematic approach to in liver enzyme activities should be con- Laboratory Screening interpretation of increased liver enzyme sidered in addition to the pattern. Mildly Page 418 activities is outlined in FIGURE 1. The first increased activity of a single liver enzyme Additional Testing step is to develop an integrated clinical in a clinically asymptomatic dog may be Page 420 picture based on the patient’s signalment, spurious and should be rechecked. Lipemia history, clinical signs, and concurrent lab- and hemolysis may falsely increase activi- Diagnostic Imaging Page 422 oratory abnormalities. Careful evaluation ties of serum liver enzymes and should be of this picture aids in ranking diagnostic considered when interpreting laboratory Liver Sampling Techniques Page 422 differentials. data. Because increases in hepatocellular Increases in liver enzyme activities are leakage enzyme activity are proportional Diagnostic Sampling categorized as cholestatic, hepatocellular to the severity of damage, increases greater Page 422 leakage, or mixed. A cholestatic or induc- than twice the reference interval warrant ible pattern is characterized by predomi- further scrutiny. Increased activity of mul- nant increases in alkaline phosphatase tiple liver enzymes, particularly if a hepato- (ALP) and γ-glutamyl transpeptidase (GGT) cellular or mixed pattern of injury is present, activities. A hepatocellular leakage pat- also warrants close attention because of an *A companion article, “Liver En- tern has predominant increases in the increased likelihood of severe disease. zyme Elevations in Dogs: Physi- activities of alanine aminotransferase ology and Pathophysiology,” be- (ALT) and aspartate aminotransferase Signalment, History, and gins on page 408. (AST) secondary to hepatocyte injury or Physical Examination aDr. Whittemore discloses that she has received financial sup- necrosis. A mixed pattern of liver enzyme Once spurious or self-limiting increases port from Heska Corporation. activity increase suggests concurrent hep- of liver enzyme activities have been ruled 416 Compendium: Continuing Education for Veterinarians® | September 2009 | CompendiumVet.com FREE Liver Enzyme Elevations in Dogs: Diagnostic Approach CE FIGURE 1 Vascular anomalies Intrahepatic cholestasis Inflammatory/immune disorders Metal storage disorders Amyloidosis Neoplasia Vascular anomalies Step 2: Step 3: Step 3: Step 4: Flowchart demonstrating a stepwise approach to the evaluation of increased activities of liver enzymes. Blue differen- tials are etiologies that may require a comprehensive hepatobiliary evaluation for diagnosis. CompendiumVet.com | September 2009 | Compendium: Continuing Education for Veterinarians® 417 FREE CE Liver Enzyme Elevations in Dogs: Diagnostic Approach BOX 1 the onset of injury.1 Liver injury may worsen Breeds Associated With for days or weeks following withdrawal of the medication before improvement is seen. Increased Activities of Repeat challenge with a suspected hepato- Liver Enzymesa toxin may greatly exacerbate hepatotoxicosis. Alternatively, a patient may develop tolerance Hepatocellular leakage pattern for a hepatotoxin and have negative challenge Idiopathic hepatitis results. If potential hepatotoxins are identified, ❯ American and English cocker spaniels they should be discontinued and liver enzyme ❯ Labrador retriever activities reassessed in 2 to 3 weeks. ❯ Standard poodle The patient’s vaccination history and poten- Copper-associated hepatitis tial exposure to infectious agents should be ❯ Bedlington terrier determined. Hepatopathies have been docu- ❯ Dalmatian mented with Leptospira interrogans serovars ❯ Doberman pinscher Icterohaemorrhagiae and Pomona and Lepto- ❯ Labrador retriever spira kirschneri serovar Grippotyphosa2; addi- ❯ Skye terrier tional associations may be identified with ❯ West Highland white terrier increased molecular testing. Canine adenovi- Amyloidosis rus 1 infection, heartworm disease, ehrlichio- QuickNotes ❯ Chinese shar-pei sis, leishmaniasis, neosporosis, toxoplasmosis, Supplements, and systemic mycoses should be considered Cholestatic pattern as potential causes of hepatocellular disease.3,4 nutraceuticals, and Benign hyperphosphatasemia In dogs, bacterial infections arise primarily topical medications ❯ Scottish terrier from hematogenous routes and breaks in host are easily over- ❯ Siberian husky defenses, such as periodontal disease.5 Hyperlipidemia looked as potential Lethargy, inappetence, vomiting, and diar- ❯ Miniature schnauzer hepatotoxins. rhea are common clinical signs. Icterus, ascites, Gallbladder disease acholic feces, or hepatic encephalopathy may ❯ Shetland sheepdog occur with acute liver failure or progression a This list does not include breeds associated with congenital of chronic disease. Physical examination may vascular abnormalities, which commonly have mixed liver enzyme be unremarkable or may reveal abnormali- activity patterns. ties consistent with an extrahepatic disorder. Poor body condition, icterus, abdominal pain, out, the patient should be evaluated for breed hepatomegaly or microhepatia, and abdomi- associations (BOX 1). A careful dietary history nal effusion may suggest hepatic dysfunc- may identify risk factors for infection (e.g., raw tion. The presence of clinical signs, physical or undercooked meat) or intoxication (e.g., examination abnormalities, or evidence of poor food storage practices, recalled diets). decreased liver function should prompt an Depending on the geographic location, access expeditious workup to maximize chances of to Amanita mushrooms and cycad palm plants obtaining a diagnosis and successful thera- should be determined. The owner should be peutic intervention. carefully questioned about medications to which the patient may have access, including Laboratory Screening supplements, nutraceuticals, and topical gluco- A minimum database of a complete blood corticoids. Owners may not notice a pet’s con- count (CBC), biochemical profile, and urinaly- sumption of prescription medications or know sis should be obtained for dogs with verified that common items for human use, such as increased activities of liver enzymes. those containing xylitol, can be hepatotoxic. Hepatobiliary disease can be associated Diagnosis of drug-related hepatotoxicity with a variety of CBC abnormalities. Although can be challenging. The time between initial gastrointestinal bleeding or coagulopathy sec- administration of a medication and detection ondary to hepatobiliary dysfunction may stim- of hepatic injury can vary greatly, which makes ulate a regenerative anemia, the chronicity of it difficult to establish exposure preceding many hepatic diseases often leads to anemia 418 Compendium: Continuing Education for Veterinarians® | September 2009 | CompendiumVet.com FREE CE Liver Enzyme Elevations in Dogs: Diagnostic Approach of chronic disease, which is nonregenerative. Additional Testing Microcytosis is common with acquired or con- Thorough evaluation of liver enzyme activity genital portosystemic shunts.6 Thrombocytosis increases may require additional testing for occurs with hyperadrenocorticism,7 chronic extrahepatic and hepatobiliary diseases after blood loss, and inflammatory disorders,8 and integration of the minimum database with the thrombocytopenia suggests ongoing vasculitis clinical presentation. Hyperadrenocorticism and or consumptive processes. hypothyroidism should be considered in dogs Biochemical changes may aid in the dif- with appropriate clinical findings and chole- ferentiation of extrahepatic and hepatobiliary static enzyme activity increases. Thyroid hor- disease. Concentrations of bilirubin, choles- mone testing should be interpreted carefully terol, blood urea nitrogen (BUN), albumin, because sick euthyroid syndrome is common and glucose provide information about liver in dogs with chronic disease. Dogs with gas- function despite low sensitivity and specificity. trointestinal signs should be evaluated for pan- In the absence of hemolysis or sepsis, hyper- creatitis and primary gastrointestinal disease. bilirubinemia indicates cholestasis due to Depending on risk assessment and vaccina- hepatobiliary disease or posthepatic obstruc- tion history, infectious disease screening may tion. Cholesterol concentrations
Recommended publications
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Public Use Data Tape Documentation 1992 National Ambulatory Medical Care Survey
    Public Use Data Ta~e Documentation 1992 National Ambulatory Medical Care Survey From the CENTERS FOR DISEASE CONTROL AND PREVENTION/Nutional Center for Health Stdklics -—..—=-.=-=.-.‘,.- . ----. - . .- -,-- -.-- .--.,. -’ ‘ --- - –.--.------ ,-:-.-,J ----- ---------- ---P ------.-->- — .. ..- --. : _ U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Publlc Health Service Centers for Disease Control and Prevention National Center for Health Statistics CDCcE141EmFonmEUEcoumoL WMEmmm Public Use Data Tape Documentation 1992 National Ambulatory Medical Care Survey U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention National Center for Health .SJatistics Hyattsville, Maryland November 1994 299 2 NAMcs MICRO-DATA TAPE Docum NTATION PAGE 1 ABSTRACT This material provides documentation for users of the Micro-Data tapes of the National Ambulatory Medical Care Suney (NAMCS) conducted by the National Center for Health Statistics. Section I, “Description of the National Ambulatory Medical Care Sumey,” includes information on the scope of the amm.rey,the sample, field activities, data collection procedures, medical coding procedures, population estimates, and sampling errors. Section II provides technical detaile of the tape (number of tracks, record length, etc.), and a detailed description of the contents of each data record by location. Section III contains marginal data or estimates for each item on the data record in Section II. The appendixes contain santplingerrors, instructions and definitions for completing the Patient Record Form, and list~ of codes used in the survey. TABLE OF CONTENTS PAGE I. Description of the National Ambulatory Medical Care SuNey 2-14 Distribution of physicians (Table I) 4 Population Figures (Table II) 6 Patient Log and Patient Record Form (Figure 1) 8 References 14 II.
    [Show full text]
  • Motor Activity and Threshold and Tolerance to Experimentally Induced Pain in Healthy Man
    Gut: first published as 10.1136/gut.25.5.513 on 1 May 1984. Downloaded from Gut, 1984, 25, 513-519 Ceruletide increases dose dependently both jejunal motor activity and threshold and tolerance to experimentally induced pain in healthy man G STACHER, H STEINRINGER, G SCHMIERER, C SCHNEIDER, S WINKLEHNER, G MITTELBACH, C DE PAOLIS, AND C PRAGA From the Psychophysiology Unit at the Psychiatric and First Surgical Clinic, University of Vienna, Vienna, Austria, and Farmitalia Carlo Erba, Milano, Italy SUMMARY The effects of ceruletide on jejunal motility and experimentally induced pain were studied in 16 healthy men, who participated each in four experiments and received in random double blind fashion 5, 10, or 20 ,g ceruletide intramuscularly or placebo. Jejunal pressures were recorded by three perfused catheters with orifices between 10 and 20 cm aboral of the ligament of Treitz. Ceruletide dose dependently diminished phase I and increased phase II type activity and tended to reduce the number, but not the duration, of activity fronts. The number and amplitude of contractions as well as the area under the curve increased significantly and dose dependently as did threshold and tolerance to electrically and threshold to thermally induced pain. Only mild sedative and other side effects occurred. Ceruletide (INN proposed by the WHO) or, as it produce a decrement in response to noxious stimula- http://gut.bmj.com/ was named formerly, caerulein is a decapeptide of tion,15 16 in man ceruletide yields prompt and the amino acid sequence Pyr-Gln-Asp-Tyr(SO3H)- complete relief of pain not only from biliary1 19 but Thr-Gly-Trp-Met-Asp-Phe-NH2 and is structurally also from renal colics,17 abolishes cancer pain, 20 and related to the cholecystokinin (CCK) - gastrin alleviates experimentally induced pain.2' 22 The family.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
    INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 15/06/2006 INTERNATIONAL NONPROPRIETARY NAMES (INN) FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES (A REVIEW) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines (QSM) Medicines Policy and Standards (PSM) Department CONTENTS 0. INTRODUCTION…………………………………….........................................................................................v 1. PHARMACOLOGICAL CLASSIFICATION OF BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES……………………………………................................1 2. CURRENT STATUS OF EXISTING STEMS OR SYSTEMS FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES…………………….3 2.1 Groups with respective stems ……………………………………………………………………3 2.2 Groups with respective pre-stems………………………………………………………………4 2.3 Groups with INN schemes………………………………………………………………………….4 2.4 Groups without respective stems / pre-stems and without INN schemes…..4 3. GENERAL POLICIES FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES……………………………………………………………………………………………………...5 3.1 General policies for blood products……………………………………………………………5 3.2 General policies for fusion proteins……………………………………………………………5 3.3 General policies for gene therapy products………………………………………………..5 3.4 General policies for glycosylated and non-glycosylated compounds………...6 3.5 General policies for immunoglobulins……………………………………………………….7 3.6 General polices for monoclonal antibodies………………………………………………..7 3.7 General polices for skin substitutes……………………………………………………………9 3.8 General policies for transgenic products……………………………………………………9
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Cholecystitis Without Gallstones
    HPB Surgery 1990, Vol. 2 pp. 83-103 1990 Harwood Academic Publishers GmbH Reprints available directly from the publisher Printed in the United Kingdom Photocopying permitted by license only REVIEW ARTICLE CHOLECYSTITIS WITHOUT GALLSTONES J-Y. KANG* AND R.C.N. WlLLIAMSON Department of Surgery, Royal Postgraduate Medical School and Hammersmith Hospital, London, U.K. (Received 29 May 1989) INTRODUCTION Some degree of cholecystitis is inevitably found in gallbladders that contain calculi. Yet both acute and chronic inflammation, of the gallbladder can arise in the absence of stones. Acute acalculous choleycstitis is a dangerous disease that is sometimes encountered among seriously ill patients who are kept alive in a surgical intensive therapy unit. Chronic acalculous cholecystitis is a rather shadowy entity, but it certainly accounts for some patients with "typical" biliary pain in whom investiga- tions are repeatedly negative for gallstones. Identification of such patients is diffi- cult but worthwhile, because cholecystectomy is as likely to be curative as it is in calculous disease. Occasionallly there is a clear-cut cause for acalculous inflamma- tion of the gallbladder, such as a specific bacteraemia or mechanical obstruction of the cystic duct. This review will consider the acute and chronic types of acalculous cholecystitis plus these secondary forms of the disease, terminating with a brief discussion of cholecystitis without gallstones in paediatric practice. ACUTE ACALCULOUS CHOLEYCYSTITIS Epidemiology Approximately 10 per cent of
    [Show full text]